Jazz gets first FDA nod for HER2 bispecific Ziihera
Jazz Pharma has claimed FDA approval for its HER2-directed bispecific antibody Ziihera as a treatment for biliary tract cancer
Newsletters and Deep Dive digital magazine
Jazz Pharma has claimed FDA approval for its HER2-directed bispecific antibody Ziihera as a treatment for biliary tract cancer
9th Liquid Biopsy for Precision Oncology Summit | February 18-20, 2025 | San Diego, CA | FREE* to Attend for Biopharma
Novartis has raised its guidance for sales growth out to 2029 on the strength of its pipeline and the potential of late-stage R&D assets
Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the FGFR-targeting drug
Discover the latest treatments, clinical trials, and top healthcare professionals sharing insights on social media from the ESMO 2024 conference.
Editor's Picks
Newsletters and Deep Dive
digital magazine